This trial is active, not recruiting.

Condition neoplasms
Treatment bi 6727
Phase phase 1
Sponsor Boehringer Ingelheim
Start date November 2005
End date January 2009
Trial size 65 participants
Trial identifier NCT02273388, 1230.1, 2005-002500-42


The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection of overall safety and antitumour efficacy data and the determination of the pharmacokinetic profile of BI 6727.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Masking open label
Primary purpose treatment
bi 6727

Primary Outcomes

maximum tolerated dose (MTD) as defined by dose limiting toxicity
time frame: 3weeks of first cycle

Secondary Outcomes

Tumour response to therapy
time frame: assessed every 6 weeks, average time of 4 months
progression free survival
time frame: assessed every 6 weeks, average time of 4 months
QTc changes in a subgroup of 14 patients treated at MTD
time frame: 6 weeks (two first cycles)
pharmacokinetic parameters: area under the curve 0-24h
time frame: 6 weeks(two first cycles)
pharmacokinetic parameters: Maximum concentration
time frame: 6 weeks(two first cycles)
pharmacokinetic parameters: termination half life
time frame: 6 weeks(two first cycles)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: 1. Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment 2. Age 18 years or older 3. Written informed consent consistent with ICH-GCP and local legislation 4. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2 5. Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies (except alopecia) The 18 additional patients recruited at the MTD must also meet the following criterion: 6. Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI) Exclusion criteria: 1. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol 2. Pregnancy or breastfeeding 3. Active infectious disease or known chronic Hepatitis B/Hepatitis C infection 4. Clinical evidence of active brain or leptomeningeal disease during the past 12 months 5. Second malignancy currently requiring active therapy 6. Absolute neutrophil count less than 1500 / mm3 7. Platelet count less than 100 000 / mm3 8. Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent) 9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal) 10. Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent) 11. Known history of relevant QT-prolongation, e.g. long QT-syndrome 12. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception 13. Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug) 14. Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates. 15. Patients unable to comply with the protocol 16. Active alcohol or drug abuse

Additional Information

Official title An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Boehringer Ingelheim.